Dainippon Sumitomo raises guidance on US Latuda growth
This article was originally published in Scrip
Executive Summary
Dainippon Sumitomo Pharma (DSP) has raised its financial guidance for the fiscal year ending 31 March, mainly on stronger than expected US sales of its atypical antipsychotic Latuda (lurasidone).